Health care reform initiatives in their various forms tend to agree that cost-effectiveness and expanded patient access are important goals. To serve these ends, in recent years there has been a trend for device developers to take proven therapies or procedures and re-engineer them in ways that make them simpler, less expensive and easier to use, while delivering therapy that is at least equivalent to current treatment.
Such products are emerging in diabetes, with low-cost, disposable insulin pumps (like that of Valeritas Inc., which recently raised a $150 million Series C round [See Deal]) for...